In a 45-year-old man with rheumatic heart disease and symptomatic severe mitral regurgitation (NYHA class III–IV), mild left ventricular dilation, left ventricular ejection fraction 45%, already on optimized medical therapy (furosemide, spironolactone, enalapril, carvedilol), what is the best next step in management?

Mitral Valve Replacement

This patient requires mitral valve replacement (or repair if feasible) as the best next step in management. 1

Rationale for Surgical Intervention

This 45-year-old man meets multiple Class I indications for mitral valve surgery based on the 2020 ACC/AHA guidelines:

Primary Indications Met:

1. Symptomatic severe primary MR - He has NYHA class III-IV symptoms (dyspnea, orthopnea, PND) despite optimal medical therapy 1

2. Reduced LVEF (45%) - This is below the 60% threshold that mandates intervention even in asymptomatic patients. The guidelines clearly state that surgical intervention is indicated when LVEF falls to <60% 1

3. Already on guideline-directed medical therapy (GDMT) - The patient is optimized on furosemide, spironolactone, enalapril, and carvedilol, yet remains symptomatic. Medical therapy alone has no proven role in altering the natural history of severe primary (rheumatic) MR 2

Why Not the Other Options:

• Digoxin (Option A): Has no role in severe MR management unless there is concurrent atrial fibrillation with rate control issues. It does not address the underlying valvular pathology and will not prevent progressive LV dysfunction 1

• Losartan (Option B): While ACE inhibitors (already on enalapril) or ARBs may have theoretical benefit in secondary MR, there is no established role for vasodilators in primary/rheumatic MR 2, 3. Switching from enalapril to losartan offers no advantage and delays definitive treatment

• Follow-up in 6 months (Option C): This is inappropriate and dangerous. The patient has already crossed critical thresholds (symptomatic + LVEF <60%). Delaying surgery risks irreversible LV dysfunction and significantly worse outcomes 1, 2

Critical Timing Considerations

The window for optimal surgical intervention is closing. Research demonstrates that:

• Once LVEF drops below 60% in severe MR, myocardial dysfunction may become irreversible even after successful valve surgery 2
• Symptomatic patients with severe MR have only 45% 5-year survival without surgical intervention 3
• Surgical outcomes are significantly better when performed before symptoms develop or LV function deteriorates 1

This patient has both adverse features (symptoms AND reduced LVEF), making immediate referral for surgery imperative.

Surgical Approach

For rheumatic mitral disease:

• Mitral valve replacement is typically required due to the structural valve damage characteristic of rheumatic disease 4
• Repair may be considered if valve anatomy is favorable, though rheumatic pathology often precludes successful repair
• The patient should be referred to a comprehensive valve center with experienced mitral valve surgeons 1

Common Pitfalls to Avoid

1. Waiting for further LV deterioration - LVEF of 45% already indicates significant myocardial dysfunction that may not fully recover post-operatively 5

2. Over-relying on medical optimization - While GDMT is appropriate for heart failure symptoms, it does not address the mechanical problem of severe MR and cannot prevent progressive ventricular remodeling 6, 2

3. Misclassifying as secondary MR - This is primary (rheumatic) MR with secondary LV dysfunction from chronic volume overload, not functional MR from cardiomyopathy. The treatment paradigm is fundamentally different 1

Immediate referral to cardiac surgery is the standard of care for this patient.